Neurent Medical raises €62.5M oversubscribed Series C to commercialize NEUROMARK for chronic rhinitis — FDA next-gen cleared
Summary
Neurent Medical closed an oversubscribed €62.5M Series C in February 2026 for commercial expansion of NEUROMARK RF posterior nasal nerve ablation for chronic rhinitis. Next-gen NEUROMARK cleared by FDA in June 2025. RCT shows 76% 2-year responders. Successful commercial validation with general ENTs and academic rhinologists complete. 1 in 4 Americans has chronic rhinitis with limited durable treatment options.
Why it matters
Oversubscribed €62.5M for a commercial-stage ENT device demonstrates that investors see NEUROMARK as a commercial scaling story rather than a clinical development risk. An oversubscribed round in this size range with a commercial-stage medtech company reflects the market's confidence in the revenue trajectory — investors competed to get into this round.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial